β-Amyloid (11H3): sc-81437



The Power to Question

BACKGROUND

Proteolytic cleavage of the Amyloid protein precursor (APP) gives rise to the β -Amyloid and Amyloid A4 proteins, which are present in human platelets. Amyloid deposition is associated with type II diabetes, Down syndrome and a variety of neurological disorders, including Alzheimer's disease. The Amyloid precursor protein (APP) undergoes alternative splicing, resulting in several isoforms. Proteolytic cleavage of APP leads to the formation of the Amyloid β /A4 Amyloid protein. This protein is involved in the formation of neurofibrillary tangles and plaques that characterize the senile plaques of Alzheimer's patients. APLP1 (Amyloid precursor-like protein 1) and APLP2 are structurally similar to APP. Human APLP2 is a membrane-bound sperm protein that contains a region highly homologous to the transmembrane-cytoplasmic domains of APP found in brain plaques of Alzheimer's disease patients.

REFERENCES

- Kosik, K.S. 1992 Alzheimer's disease: a cell perspective. Science 256: 780-783.
- 2. Dyrks, T., Dyrks, E., Monning, U., Urmoneit, B., Turner, J. and Beyreuther, K. 1993. Generation of β /A4 from the Amyloid protein precursor and fragments thereof. FEBS Lett. 335: 89-93.
- Hirai, S. and Okamoto, K. 1993. Amyloid β/A4 peptide associated with Alzheimer's disease and cerebral Amyloid angiopathy. Intern. Med. 32: 923-925.
- Arendt, T., Holzer, M., Fruth, R., Bruckner, M.K. and Gartner, U. 1995.
 Paired helical filament-like phosphorylation of Tau, deposition of β/A4-Amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A. Neuroscience 69: 691-698.
- Gillmore, J.D., Hawkins, P.N. and Pepys, M.B. 1997. Amyloidosis: a review of recent diagnostic and therapeutic developments. Br. J. Haematol. 99: 245-256.
- 6. van Leeuwen, F.W., de Kleijn, D.P., van den Hurk, H.H., Neubauer, A., Sonnemans, M.A., Sluijs, J.A., Koycu, S., Ramdjielal, R.D., Salehi, A., Martens, G.J., Grosveld, F.G., Peter, J., Burbach, H. and Hol, E.M. 1998. Frameshift mutants of β-Amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 279: 242-247.
- Tamboli, I.Y., Prager, K., Barth, E., Heneka, M., Sandhoff, K. and Walter, J. 2005. Inhibition of glycosphingolipid biosynthesis reduces secretion of the β-Amyloid precursor protein and Amyloid β-peptide. J. Biol. Chem. 280: 28110-28117.
- 8. LocusLink Report (LocusID: 351). http://www.ncbi.nlm.nih.gov/LocusLink/

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

CHROMOSOMAL LOCATION

Genetic locus: APP (human) mapping to 21q21.3.

SOURCE

 β -Amyloid (11H3) is a mouse monoclonal antibody raised against the N-terminus of β -Amyloid of human origin.

PRODUCT

Each vial contains 50 μg lgG_1 in 500 μl of PBS with < 0.1% sodium azide, 1% gelatin, PEG and sucrose.

APPLICATIONS

 β -Amyloid (11H3) is recommended for detection of extracellular β -Amyloid soluble peptide cleavage product of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000); non cross-reactive with amyloid precursor protein (APP).

Suitable for use as control antibody for APP siRNA (h): sc-29677.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-mouse IgG-HRP: sc-2005 (dilution range: 1:2000-1:32,000) or Cruz Marker™ compatible goat anti-mouse IgG-HRP: sc-2031 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use goat anti-mouse IgG-FITC: sc-2010 (dilution range: 1:100-1:400) or goat anti-mouse IgG-TR: sc-2781 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941. 3) Immunohistochemistry: use ImmunoCruz™: sc-2050 or ABC: sc-2017 mouse IgG Staining Systems.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com